(1S,2R,5R)-2-(2-chloroethyl)-5-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-1-methyl-7-oxa-4-azabicyclo[3.2.0]heptane-3,6-dione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,2R,5R)-2-(2-chloroethyl)-5-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-1-methyl-7-oxa-4-azabicyclo[3.2.0]heptane-3,6-dione
• 英文别名: 4-(2-chloroethyl)-1-[cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
• 化学式: C₁₅H₂₀ClNO₄
• 分子量: 313.77
• InChiKey: NGWSFRIPKNWYAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF
  申请人：Ling Taotao

  公开号：US20090234137A1

  公开（公告）日：2009-09-17

  The present application relates to certain compounds and to methods for the preparation of certain compounds that can be used in the fields of chemistry and medicine. Specifically, described herein are methods for the preparation of various compounds and intermediates, and the compounds and intermediates themselves. More specifically, described herein are methods for synthesizing Salinosporamide A and its analogs that includes forming a compound of formula (VIII).

  本申请涉及某些化合物以及用于制备可用于化学和医药领域的某些化合物的方法。具体来说，本文描述了用于制备各种化合物和中间体的方法，以及这些化合物和中间体本身。更具体地，本文描述了一种合成Salinosporamide A及其类似物的方法，其中包括形成化合物的公式（VIII）。
• CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS
  申请人：Romo Daniel

  公开号：US20090062547A1

  公开（公告）日：2009-03-05

  The present invention provides a concise synthetic method for generating lactam-fused beta-lactones that feature, in some embodiments, a tertiary fused carbinol, quaternary carbons, and a reactive beta-lactone moiety available for further reactions. The present invention further provides compounds synthesized by this method as well as methods of using these compounds as inhibitors of the proteasome and fatty acid synthase.

  本发明提供了一种简洁的合成方法，用于生成具有乳内酰胺融合的β-内酯，其中在某些实施例中具有第三级融合的碳醇，四元碳和可用于进一步反应的活性β-内酯基团。本发明还提供了通过该方法合成的化合物，以及使用这些化合物作为蛋白酶体和脂肪酸合成酶的抑制剂的方法。
• Salinosporamides and methods for use thereof
  申请人：The Regents Of the University of California

  公开号：EP2441767A1

  公开（公告）日：2012-04-18

  The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hypoproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

  本发明基于以下发现：海洋放线菌 CNB392 和 CNB476 菌株的某些发酵产物是哺乳动物细胞增殖低下的有效抑制剂。CNB392 和 CNB476 菌株属于小孢子菌科（Micromonosporaceae），人们为这一海洋放线菌属提出了一个统称 Salinospora。该菌株产生的反应产物被归类为盐孢酰胺，由于其分子量低、IC50 值低、药效高，且对癌细胞的选择性高于真菌，因此在治疗肿瘤性疾病方面特别有优势。
• Salt formulations for the fermentation of marine microorganisms
  申请人：Triphase Research and Development I Corp.

  公开号：US10011814B2

  公开（公告）日：2018-07-03

  Growth medium are disclosed for use in fermenting a marine microorganism. The medium comprise Potassium, Calcium, Strontium, Borate and Fluoride at specific concentrations. Alternatively, the growth medium comprises cobalt at specified concentrations or comprises vitamin B12 at specified concentrations. Methods of producing certain desired compound by fermentation of a marine microorganism are also disclosed.

  公开了用于海洋微生物发酵的生长培养基。培养基包括特定浓度的钾、钙、锶、硼酸盐和氟化物。另外，生长培养基还包括特定浓度的钴或特定浓度的维生素 B12。还公开了通过海洋微生物发酵生产某些所需化合物的方法。
• Salinosporamides and methods of use thereof
  申请人：The Regents of the University of California

  公开号：US10314818B2

  公开（公告）日：2019-06-11

  The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

  本发明基于以下发现：海洋放线菌 CNB392 和 CNB476 菌株的某些发酵产物是哺乳动物细胞过度增殖的有效抑制剂。CNB392 和 CNB476 菌株属于小孢子菌科（Micromonosporaceae），人们为这一海洋放线菌属提出了一个统称 Salinospora。该菌株产生的反应产物被归类为盐孢酰胺，由于分子量低、IC50 值低、药效高，而且对癌细胞的选择性高于真菌，因此在治疗肿瘤性疾病方面特别有优势。